Treatment of MEN1 with Thymic Neuroendocrine Tumour

Clinical Scenario

This protocol addresses patients with Multiple endocrine neoplasia type 1 (MEN1) who have developed a thymic neuroendocrine tumour — a recognised and particularly serious complication of MEN1.

Why This Situation Matters

Thymic neuroendocrine tumours occur in approximately 2–8% of individuals with MEN1, yet they account for a disproportionately high share of MEN1-related deaths due to their aggressive behaviour. Early recognition and appropriate management are therefore critical in this sub-population.

Treatment Approach (Overview)

For locoregional thymic neuroendocrine tumour disease in MEN1, the evidence points to a surgical approach as the primary intervention — though the full clinical algorithm, patient selection criteria, and accompanying considerations are detailed in the complete protocol.

The complete regimen — including sequencing, specific indications, and follow-up — is available via the link below.